Search clinical trials for: E7080

Total 151 results

Eisai Inc.

Terminated

A Study of E7050 in Combination With E7080 in Participants With Advanced Solid Tumors (Dose Escalation) and in Participants With Recurrent Glioblastoma or Unresectable Stage III or Stage IV Melanoma After Prior Systemic Therapy (Expansion Cohort and Phase 2)

Advanced Solid Tumors

United States
Eisai Limited

Completed

A Study to Determine the Metabolism and Elimination of [14C]E7090 in Healthy Male Participants

Healthy Volunteers

United Kingdom
Eisai Co., Ltd.

Completed

A Multicenter, Open-label Study for E7040 in Japanese Subjects With Hypervascular Tumor and Subjects With Arteriovenous Malformation

Hypervascular Tumor and Arteriovenous Malformation

Japan
Eisai Inc.

Completed

A Dose-Finding Study of E7050 Administered Orally to Patients With Advanced Solid Tumors

Cancer

United Kingdom
Eisai Co., Ltd.

Completed

Phase 1 Study of E7090 in Subjects With Solid Tumor

Tumors

Japan
Eisai Co., Ltd.

Completed

A Study of E7050 Administered Orally to Patients With Advanced Solid Tumors

Solid Tumors

Japan
Eisai Limited

Completed

Pharmacokinetics and Food Effect of Single Oral Dose of E7050 in Healthy Volunteers

Healthy Subjects

Netherlands
Eisai Co., Ltd.

Completed

A Phase I Study of E7050 in Subjects With Solid Tumors

Gastric Cancer | Solid Tumor

Japan
Eisai Co., Ltd.

Completed

Post-marketing Surveillance of DC Bead in Patients With Hepatocellular Carcinoma

Hepatocellular Carcinoma

Japan
Emory University
National Cancer Institute (NCI); Eisai Co., Ltd.

Recruiting

Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant

Unresectable Hepatocellular Carcinoma | Recurrent Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC... and other conditions

United States
Emory University
Eisai Inc.

Terminated

Lenvatinib and Iodine Therapy in Treating Patients With Radioactive Iodine-Sensitive Differentiated Thyroid Cancer

Differentiated Thyroid Gland Carcinoma | Thyroid Gland Follicular Carcinoma | Thyroid Gland Papillary Carcinoma

United States
National Cancer Center, Japan
Eisai Co., Ltd.

Active, not recruiting

NCCH2006/MK010 Trial (FORTUNE Trial)

Advanced or Recurrent Solid Tumors | FGFR Gene Alterations

Japan
Eisai Co., Ltd.

Active, not recruiting

A Study of E7090 in Participants With Unresectable Advanced or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor (FGFR) 2 Gene Fusion

Cholangiocarcinoma

China, Japan
Mayo Clinic
National Cancer Institute (NCI)

Completed

Lenvatinib in Treating Patients With Metastatic or Advanced Pheochromocytoma or Paraganglioma That Cannot Be Removed by Surgery

Metastatic Adrenal Gland Pheochromocytoma | Malignant Adrenal Gland Pheochromocytoma | Malignant Paraganglioma

United States
M.D. Anderson Cancer Center

Recruiting

Pembrolizumab and Lenvatinib for the Treatment of Serous Ovarian Cancer Patients

Recurrent Primary Peritoneal High Grade Serous Adenocarcinoma | High Grade Ovarian Serous Adenocarcinoma | Recurrent High Grade Fallopian Tube Serous Adenocarcinoma | Recurrent High Grade Ovarian Serous Adenocarcinoma | High Grade Fallopian Tube Serous Adenocarcinoma | Peritoneal High Grade...

United States
M.D. Anderson Cancer Center

Recruiting

Pembrolizumab and Lenvatinib for the Treatment of Advanced, Unresectable, or Metastatic Gastroesophageal Adenocarcinoma

Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage IV Gastric Cancer AJCC v8 | Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 | Metastatic Gastric Adenocarcinoma | Metastatic Gastroesophageal Junction... and other conditions

United States
Eisai Co., Ltd.

Completed

Study of Lenvatinib (E7080) in Participants With Advanced Hepatocellular Carcinoma (HCC)

Hepatocellular Carcinoma

Japan, Korea, Republic of
Eisai Inc.

Completed

A Pharmacokinetic and Safety Study of E7080 in Subjects With Mild (10 mg), Moderate (10 mg), and Severe Hepatic Impairment (5 mg) and Normal Hepatic Function (10 mg)

Hepatic Impairment | Hepatic Function

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Lenvatinib and Pembrolizumab for the Treatment of Stage IVB Locally Advanced and Unresectable or Stage IVC Metastatic Anaplastic Thyroid Cancer

Poorly Differentiated Thyroid Gland Carcinoma | Thyroid Gland Squamous Cell Carcinoma | Unresectable Thyroid Gland Carcinoma | Metastatic Thyroid Gland Carcinoma | Stage IVB Thyroid Gland Anaplastic Carcinoma AJCC v8 | Stage IVC Thyroid Gland Anaplastic Carcinoma AJCC v8

United States
Eisai Inc.

Completed

Study of the Safety and Activity of Lenvatinib (E7080) in Subjects With KIF5B-RET-Positive Adenocarcinoma of the Lung

KIF5B-RET-Positive Adenocarcinoma of the Lung

United States, Hong Kong, Japan, Taiwan, Singapore
Eisai Inc.

Approved for marketing

An Expanded Access Program With Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer

Differentiated Thyroid Cancer

United States
Eisai Inc.

Completed

A Phase I/Ib, Multicenter, Open-Label, Dose Escalation Study of E7080 in Patients With Solid Tumors and in Combination With Temozolomide in Patients With Advanced and/or Metastatic Melanoma

Metastatic Melanoma

United States
Eisai Inc.

Completed

A Phase 1, Open-Label, Single-Dose, Pharmacokinetic and Safety Study of E7080 (24 mg) Administered to Subjects With Mild, Moderate, and Severe Renal Impairment and to Healthy Subjects

Renal Impairment | Disease Severity

United States
Humanity & Health Medical Group Limited
Beijing 302 Hospital; Kindai University Faculty of Medicine

Terminated

Safety and Efficacy of Lenvatinib in Subjects With HCC Progression After First Line Treatment With Checkpoint Inhibitors

Hepatocellular Carcinoma

Hong Kong
Eisai Inc.

Completed

A Post-marketing Observational Study on Risk Factors for Hepatic Encephalopathy in Participants With Unresectable Hepatocellular Carcinoma

Carcinoma, Hepatocellular

Japan
Eisai Inc.

Completed

An Open-Label, 2-Cohort, Multicenter, Study of Lenvatinib in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma

Stage IV Melanoma | Unresectable Stage III

United States, United Kingdom, Australia, Germany
Eisai Inc.

Completed

Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression

Endometrial Cancer

United States, Poland, Ukraine, Bulgaria, Romania, Belgium, Russian Federation, Hungary
Eisai Co., Ltd.

Completed

A Study of Overall Survival in Participants With Unresectable Hepatocellular Carcinoma

Neoplasms | Carcinoma | Neoplasms, Glandular and Epithelial | Carcinoma, Hepatocellular

Japan
Eisai Inc.

Completed

Crossover Study to Evaluate the Relative Bioavailability and Palatability of a Lenvatinib Suspension Compared to the Capsule Formulation in Adult Healthy Volunteers

Healthy Volunteers

United States
Teresa Helsten, MD
Eisai Co., Ltd.

Withdrawn

Study of Lenvatinib in Patients With Advanced Cancer and Aberrations in FGF/FGFR Signaling

Cancer

United States
Eisai Co., Ltd.

Completed

A Study of E7080 in Subjects With Solid Tumor

Cancer

Japan
Eisai Inc.

Completed

An Open Label Dose Escalation Study Of E7080

Solid Tumor or Lymphoma

United Kingdom, Netherlands
Children's Oncology Group
National Cancer Institute (NCI)

Completed

ABT-751 in Treating Children With Neuroblastoma That Has Relapsed or Not Responded to Previous Treatment

Recurrent Neuroblastoma | Disseminated Neuroblastoma

United States, Canada
Eisai Co., Ltd.

Completed

A Study of E7080 in Subjects With Advanced Thyroid Cancer

Thyroid Cancer

Japan
Peking Union Medical College Hospital

Completed

Lenvatinib in Patients With Previously Treated Advanced Biliary Tract Cancer (LENABC)

Cholangiocarcinoma | Biliary Tract Cancer | Targeted Therapy

China
Eisai Co., Ltd.

Completed

Post-marketing Surveillance of Lenvatinib Mesylate (Lenvima Capsule) in Patients With Unresectable Thyroid Cancer (Study LEN01T)

Thyroid Neoplasms

Japan
Eisai Inc.

Completed

E7080 Food Effect Study in Healthy Subjects

Cancer

United States
Merck Sharp & Dohme LLC
Eisai Inc.

Active, not recruiting

A Study of Lenvatinib (MK-7902) in Pediatric Participants With Relapsed or Refractory Solid Malignancies (MK-7902-013/E7080) (E7080-G000-231)

Relapsed or Refractory Solid Tumors

United States, Argentina, Australia, Belgium, Croatia, Czechia, France, Guatemala, Hungary, Israel, Italy, Korea, Republic of, New Zealand, Peru, Russian Federation, Serbia, South Africa, Spain, Sweden, Turkey
Eisai Inc.

Completed

A Pharmacokinetic Study to Assess the Influence of P-glycoprotein Inhibition and Simultaneous CYP3A4 and P-glycoprotein Induction on E7080 Pharmacokinetics Following Single Dose Oral Administration of 24 mg E7080 to Healthy Volunteers

Healthy Volunteers | P-glycoprotein

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Lenvatinib and Pembrolizumab Maintenance Therapy for the Treatment of Patients of Advanced Unresectable Pancreatic Cancer

Stage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Stage IIA Pancreatic Cancer AJCC v8 | Stage IIB Pancreatic Cancer AJCC v8 | Advanced Pancreatic Ductal Adenocarcinoma | Unresectable Pancreatic Ductal Adenocarcinoma

United States
Eisai Inc.

Completed

An Open Label Phase I Dose Escalation Study of E7080 Administered to Patients With Solid Tumors

Cancer: Solid Tumors

Japan
Eisai Inc.

Terminated

Trial to Evaluate Safety and Efficacy of Treatment of Physician Choice (TPC) Following First-Line Treatment of Lenvatinib in Subjects With Unresectable Hepatocellular Carcinoma (uHCC)

Carcinoma, Hepatocellular

United States
Eisai Inc.
Quintiles, Inc.

Completed

A Study Comparing the Combination of the Best Supportive Care Plus E7080 Versus Best Supportive Care Alone, in Patients With Advanced Lung Cancer or Lung Cancer That Has Spread, Who Have Been Previously Treated, Unsuccessfully, With at Least 2 Different Treatments

Non-Small Cell Lung Cancer

Belgium, Korea, Republic of, Italy, United States, Hungary, United Kingdom, Czechia
Eisai Limited

Completed

A Placebo-Controlled, Double-Blind Comparative Study of E2080 in Lennox-Gastaut Syndrome Patients (Study E2080-J081-304)

Lennox-Gastaut Syndrome

Japan
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors

Neuroendocrine Neoplasm | Multiple Endocrine Neoplasia Type 1 | Advanced Carcinoid Tumor | Digestive System Neuroendocrine Neoplasm | Unresectable Carcinoid Tumor

United States
Eisai Limited
Merck Sharp & Dohme LLC

Completed

A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular Carcinoma

Hepatocellular Carcinoma (HCC)

Italy, Korea, Republic of, Poland, United States, Australia, Belgium, Canada, China, France, Germany, Hong Kong, Israel, Japan, Malaysia, Philippines, Russian Federation, Singapore, Spain, Taiwan, Thailand, United Kingdom
Eisai Inc.

Terminated

A Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC)

Thyroid Carcinoma, Anaplastic

Italy, United States, France, Australia, United Kingdom
Eisai Inc.

Completed

Bioequivalence Study to Evaluate the Impact of Varying Crystalline Polymorph Forms for the Commercial Oral Capsule Formulation of 10-mg Lenvatinib in Healthy Volunteers

Healthy Volunteers

United States
Eisai Inc.
PharmaBio Development Inc.

Completed

E7050 in Combination With Cetuximab Versus Cetuximab Alone in the Treatment of Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck

Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck

United States, Korea, Republic of, Ukraine, United Kingdom
Eisai Inc.

Recruiting

A Study of E7386 in Combination With Other Anticancer Drug in Participants With Solid Tumor

Neoplasms | Carcinoma, Hepatocellular | Liver Neoplasms | Colorectal Neoplasms | Endometrial Neoplasms

United States, Taiwan, France, Japan, Korea, Republic of

Search clinical trials for: E7080

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Papua New Guinea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations